The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Minimal residual disease (MRD) trials in colorectal cancer
Emerik Osterlund, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discsusses minimal residual disease (MRD) trials in colorectal cancer. 41 colorectal cancer MRD trials are registered: half US-based, with quarters in Asia and Europe. Half focus on localized disease, the rest on metastatic or mixed. Two main groups exist: larger traditional chemotherapy trials using established endpoints (RFS, DFS, time to recurrence), and smaller early-phase immunotherapy trials (checkpoint inhibitors, vaccines, cellular therapies) using novel ctDNA clearance endpoints for faster readouts. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
